Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 13/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24272911 | 0.82 | ADORA3 (0.44) | ADORA3ADORA1ADORA2BL3MBTL1ADORA2A | |
| SCHEMBL7026237 | 0.72 | ALDH1A1 (0.46) | ADORA3ADORA1ADORA2BL3MBTL1ADORA2A | |
| SCHEMBL25982018 | 0.71 | HSP90AA1 (0.38) | KDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL24254981 | 0.71 | HTT (0.33) | HSP90AA1HSP90AB1 | |
| SCHEMBL25527717 | 0.70 | ADORA3 (0.38) | ADORA3HSP90AA1HSP90AB1 | |
| SCHEMBL22028950 | 0.68 | HSP90AA1 (0.36) | KDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL29851065 | 0.68 | HSP90AA1 (0.36) | KDM4EHSP90AA1HSP90AB1 | |
| SCHEMBL23998421 | 0.67 | PIK3CG (0.47) | ADORA3ADORA1ADORA2BL3MBTL1ADORA2A | |
| SCHEMBL29383895 | 0.67 | PIK3CG (0.47) | ADORA3ADORA1ADORA2BL3MBTL1ADORA2A | |
| SCHEMBL2972209 | 0.67 | ADORA3 (0.47) | ADORA3ADORA1ADORA2BL3MBTL1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4716531-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | Board of Regents, The University of Texas System (US) | 2026-04-01 | — | — | EP | disclosed |
| US-20260070925-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | UNIV TEXAS (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS INC (US) | 2026-01-08 | — | — | US | disclosed |
| EP-4551577-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | Blossomhill Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| CN-119790058-A | Fused cyclic KRAS inhibitors for the treatment of diseases | 荣山医药股份有限公司 | 2025-04-08 | — | — | CN | disclosed |
| CN-119192133-A | Synthesis of quinazoline compounds | 基因泰克公司 | 2024-12-27 | — | — | CN | disclosed |
| CN-119192134-A | Synthesis of quinazoline compounds | 基因泰克公司 | 2024-12-27 | — | — | CN | disclosed |
| WO-2024243186-A2 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-11-28 | — | — | WO | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2024015262-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023173014-A1 | KRAS INHIBITORS AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173014-A1 | KRAS INHIBITORS AND THEIR USE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| CN-116057052-A | Synthesis of quinazoline compounds | 基因泰克公司 | 2023-05-02 | — | — | CN | disclosed |
| US-20220081413-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2022-03-17 | — | — | US | disclosed |
| WO-2022035790-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | GENENTECH, INC. (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220081413-A1 | SYNTHESIS OF QUINAZOLINE COMPOUNDS | COQ8A, SQSTM1, QARS1 | ADORA3 1326/4885ADORA1 2123/4885ADORA2B 2182/4885 |
| US-20260070925-A1 | HETEROCYCLIC COMPOUNDS AS NRAS INHIBITORS | NRAS, KRAS, HRAS | ADORA3 3947/4885ADORA1 4696/4885ADORA2B 4574/4885 |
| US-20260008787-A1 | FUSED RING KRAS INHIBITORS FOR TREATING DISEASE | KRAS, NRAS, HRAS | ADORA3 2152/4885ADORA1 1223/4885ADORA2B 1961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.